Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Glympse Bio is raising $45,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Caroline Loew played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Glympse Bio

Imagine a future where disease is intercepted earlier, better therapies are developed faster, people don’t become patients and patients are returned to health. At Glympse Bio, we are working to turn this future into a reality. Take a glimpse into that future, where we are taking a glimpse inside the body. We are pioneering the development of synthetic biomarkers biological sensors developed using breakthroughs in science, engineering, medicine and artificial intelligence that are bioengineered to be perfectly tunable to any disease, absolutely specific, and offer earlier measures of response to disease and treatment.

To learn more about Glympse Bio, visit http://www.glympsebio.com/

Contact:
Caroline Loew, Chief Executive Officer
617-863-3636
https://www.linkedin.com/in/carolineloew/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved